Miller Steven B

SEC source: 0001567619-18-008708 · doc1.xml · derivative · entry 9

Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,646

Underlying: Common Stock, $0.01 Par Value · 10,646 shares

Expires 2025-03-04

F7 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F7 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F6 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger.

SEC source: 0001567619-18-008708 · doc1.xml · derivative · entry 8

Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,749

Underlying: Common Stock, $0.01 Par Value · 9,749 shares

Expires 2021-03-05

F7 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F7 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F6 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger.

SEC source: 0001567619-18-008708 · doc1.xml · derivative · entry 7

Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,406

Underlying: Common Stock, $0.01 Par Value · 8,406 shares

Expires 2020-03-06

F7 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F7 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F6 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger.

SEC source: 0001567619-18-008708 · doc1.xml · derivative · entry 6

Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,566

Underlying: Common Stock, $0.01 Par Value · 12,566 shares

Expires 2019-02-27

F7 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F7 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F6 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger.

SEC source: 0001567619-18-008708 · doc1.xml · derivative · entry 5

Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,116

Underlying: Common Stock, $0.01 Par Value · 1,116 shares

Expires 2019-02-27

F7 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F7 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F6 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger.

SEC source: 0001567619-18-008708 · doc1.xml · nonDerivative · entry 4

Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,131

F5 · shares: Represents shares withheld to satisfy tax obligations upon vesting.

F1 · price: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

SEC source: 0001567619-18-008708 · doc1.xml · nonDerivative · entry 3

Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,384

F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F4 · shares: Represents shares of New Cigna Common Stock received in exchange for Express Scripts performance share units. In accordance with the terms of the Merger Agreement, each performance share unit of Express Scripts outstanding was cancelled at the Effective Time in exchange for (1) 0.2434 of a share of New Cigna Common Stock and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes.

F1 · price: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

SEC source: 0001567619-18-008708 · doc1.xml · nonDerivative · entry 2

Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,520

F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3 · shares: Represents New Cigna restricted stock units received in exchange for Express Scripts restricted stock units. In accordance with the terms of the Merger Agreement, each restricted stock unit of Express Scripts outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit of New Cigna with the same terms and conditions and relating to the number of shares of New Cigna Common Stock determined in accordance with the terms of the Merger Agreement.

F1 · price: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

SEC source: 0001567619-18-008708 · doc1.xml · nonDerivative · entry 1

Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,666

F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F1 · price: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

SEC source: 0000950138-18-000643 · edgar.xml · nonDerivative · entry 2

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,800

F1 · shares: Represents shares tendered to Company to cover Reporting Person's tax liability due upon vesting of restricted stock units previously awarded under long-term incentive plans.

SEC source: 0000950138-18-000643 · edgar.xml · nonDerivative · entry 1

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,965

SEC source: 0000950138-18-000250 · edgar.xml · nonDerivative · entry 3

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,062

F3 · shares: Represents shares tendered to Company to cover Reporting Person's tax liability due upon vesting of performance shares.

SEC source: 0000950138-18-000250 · edgar.xml · nonDerivative · entry 2

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,163

F2 · price: Vesting of performance shares granted under Express Scripts, Inc. 2011 Long-Term Incentive Plan.

SEC source: 0000950138-18-000250 · edgar.xml · nonDerivative · entry 1

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,831

F1 · price: Grant of restricted stock units pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Awards vest in three equal installments on February 28, 2019, February 28, 2020, and February 28, 2021.

SEC source: 0000950138-18-000232 · edgar.xml · derivative · entry 3

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Express Scripts Holding Company Common Stock · 20,348 shares

Expires 2018-03-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Represents options that were automatically exercised immediately prior to the expiration of the options.

F3 · price: Stock option previously awarded pursuant to Express Scripts, Inc. 2000 Long-Term Incentive Plan. Options vested in three (3) equal installments on February 28, 2012, February 28, 2013, and February 28, 2014.

F3 · derivative.exercise_date: Stock option previously awarded pursuant to Express Scripts, Inc. 2000 Long-Term Incentive Plan. Options vested in three (3) equal installments on February 28, 2012, February 28, 2013, and February 28, 2014.

SEC source: 0000950138-18-000232 · edgar.xml · nonDerivative · entry 2

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,458

F1 · shares: Represents shares tendered to Company to cover payment of exercise price and Reporting Person's tax liability due upon exercise of stock option previously awarded under long-term incentive plans.

SEC source: 0000950138-18-000232 · edgar.xml · nonDerivative · entry 1

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,343

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950138-18-000200 · edgar.xml · nonDerivative · entry 1

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,995

F1 · shares: Represents shares tendered to Company to cover Reporting Person's tax liability due upon vesting of restricted stock units previously awarded under long-term incentive plans.

SEC source: 0000950138-18-000095 · edgar.xml · derivative · entry 1

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,008.0446

Underlying: Express Scripts Holding Company Common Stock · 189.0387 shares

Expires not disclosed

F1 · security: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan.

F2 · derivative.exercise_price: Upon distribution each Phantom Stock Unit converts to one share of the Company's Common Stock.

F3 · derivative.exercise_date: Basic Company Credit by Express Scripts Holding Company to Participant's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates.

F3 · derivative.expiration_date: Basic Company Credit by Express Scripts Holding Company to Participant's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates.

SEC source: 0000950138-17-000782 · edgar.xml · nonDerivative · entry 1

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,912

F1 · shares: Represents shares tendered to Company to cover Reporting Person's tax liability due upon vesting of restricted stock units previously awarded under long-term incentive plans.

SEC source: 0000950138-17-000309 · edgar.xml · derivative · entry 4

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,347

Underlying: Express Scripts Holding Company Common Stock · 41,347 shares

Expires 2027-03-08

F4 · price: Grant of stock option pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Vests in three equal installments on February 28, 2018, February 28, 2019, and February 28, 2020.

F4 · derivative.exercise_date: Grant of stock option pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Vests in three equal installments on February 28, 2018, February 28, 2019, and February 28, 2020.

SEC source: 0000950138-17-000309 · edgar.xml · nonDerivative · entry 3

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,033

F3 · price: Grant of restricted stock units pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Awards vest in three equal installments on February 28, 2018, February 28, 2019, and February 28, 2020.

SEC source: 0000950138-17-000309 · edgar.xml · nonDerivative · entry 2

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,407

F2 · shares: Represents shares tendered to Company to cover Reporting Person's tax liability due upon vesting of performance shares.

SEC source: 0000950138-17-000309 · edgar.xml · nonDerivative · entry 1

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,827

F1 · price: Vesting of performance shares granted under Express Scripts, Inc. 2011 Long-Term Incentive Plan.

SEC source: 0000950138-17-000246 · edgar.xml · nonDerivative · entry 1

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,906

F1 · shares: Represents shares tendered to Company to cover Reporting Person's tax liability due upon vesting of restricted stock units previously awarded under long-term incentive plans.

SEC source: 0000950138-17-000100 · edgar.xml · derivative · entry 1

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,819.0059

Underlying: Express Scripts Holding Company Common Stock · 230.3516 shares

Expires not disclosed

F1 · security: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan.

F2 · derivative.exercise_price: Upon distribution each Phantom Stock Unit converts to one share of the Company's Common Stock.

F3 · derivative.exercise_date: Basic Company Credit by Express Scripts Holding Company to Participant's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates.

F3 · derivative.expiration_date: Basic Company Credit by Express Scripts Holding Company to Participant's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates.

SEC source: 0000950138-16-001484 · edgar.xml · nonDerivative · entry 1

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,638

F1 · shares: .Represents shares tendered to Company to cover Reporting Person's tax liability due upon vesting of restricted stock units previously awarded under long-term incentive plans.

SEC source: 0000950138-16-001465 · edgar.xml · derivative · entry 3

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Express Scripts Holding Company Common Stock · 21,798 shares

Expires 2017-03-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Grant of stock options pursuant to the Express Scripts, Inc. 2000 Long-Term Incentive Plan. All shares vested on February 28, 2013.

F2 · derivative.exercise_date: Grant of stock options pursuant to the Express Scripts, Inc. 2000 Long-Term Incentive Plan. All shares vested on February 28, 2013.

SEC source: 0000950138-16-001465 · edgar.xml · nonDerivative · entry 2

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,817

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.029, inclusive. The Reporting Person undertakes to provide to Express Scripts Holding Company, any security holder of Express Scripts Holding Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0000950138-16-001465 · edgar.xml · nonDerivative · entry 1

Miller Steven B · CIK 0001599611 · Sr. VP & Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,615

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.